tradmap

PCRX Financials Pacira Biosciences, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 11.1% per year over the past 5 years.
  • Net income has grown slower than revenue (-45.5% vs 11.1% per year).
  • Operating margin has contracted, at 2.6% in the latest year.
  • Free cash flow has grown 28.4% per year over the past 5 years.

Financial health

  • Total debt ($372M) exceeds cash ($159M); net debt is $214M.
  • Total debt has grown slower than revenue (-18.6% vs 11.1% per year).
  • Operating income covered interest expense 1.1× in the latest year.
  • Total debt is 3.4× EBITDA.
Revenue & net income
-$100M $313M $726M $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-15% 32% 79% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$1M $89M $179M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $345M $689M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$402M -$10M $381M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $726M $7M 79.4% 2.6% $137M $372M $159M
2024 $701M -$100M 75.7% -10.5% $179M $585M $277M
2023 $675M $42M 72.6% 13.0% $139M $522M $153M
2022 $667M $16M 70.1% 9.0% $115M $689M $104M
2021 $542M $42M 74.1% 16.6% $80M — $586M
2020 $430M $146M 72.7% 10.8% $39M — $100M
2019 $419M -$11M 74.5% 2.5% $60M — $78M
2018 $332M -$471000 73.9% 4.8% $34M — $133M
2017 $284M -$43M 69.1% -8.8% -$1M — $54M
2016 $270M -$38M 59.2% -11.9% — $109M $36M
2015 — $2M — — — $104M $54M
2014 — -$14M — — — $103M $38M
2013 — -$64M — — — $99M $13M
2012 — -$52M — — — $25M $13M
2011 — -$43M — — — $26M $46M

Valuation over time

How the market has priced PCRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 72.7 145.4 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 1.3 2.7 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S

Frequently asked questions

Is PCRX growing its revenue and profit?

Over the past 5 years, Pacira Biosciences, Inc.'s revenue has grown 11.1% per year, and net income declined 45.5% per year. These are computed facts, not advice.

How much debt does PCRX have?

As of FY2025, Pacira Biosciences, Inc. reported $372M of total debt against $159M of cash; operating income covered interest expense 1.1×.

What is PCRX's profit margin?

In FY2025, gross margin was 79.4%, operating margin 2.6%, and net margin 1.0%.

What is PCRX's P/E ratio?

As of Jun '26, Pacira Biosciences, Inc. traded at a price-to-earnings ratio of about 136.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.